These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7762084)

  • 21. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
    Schmit JC; Ruiz L; Clotet B; Raventos A; Tor J; Leonard J; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1996 Aug; 10(9):995-9. PubMed ID: 8853733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
    Karlsson AC; Deeks SG; Barbour JD; Heiken BD; Younger SR; Hoh R; Lane M; Sällberg M; Ortiz GM; Demarest JF; Liegler T; Grant RM; Martin JN; Nixon DF
    J Virol; 2003 Jun; 77(12):6743-52. PubMed ID: 12767994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Protease inhibitors of the human immunodeficiency virus].
    Roca B; Simón E
    Med Clin (Barc); 1998 Mar; 110(10):375-7. PubMed ID: 9567280
    [No Abstract]   [Full Text] [Related]  

  • 24. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
    Shafer RW; Chuang TK; Hsu P; White CB; Katzenstein DA
    AIDS Res Hum Retroviruses; 1999 Jan; 15(1):65-9. PubMed ID: 10024054
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.
    Morse GD; Catanzaro LM; Acosta EP
    Lancet Infect Dis; 2006 Apr; 6(4):215-25. PubMed ID: 16554246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saquinavir: an HIV proteinase inhibitor.
    Bragman K
    Adv Exp Med Biol; 1996; 394():305-17. PubMed ID: 8815695
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
    Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
    Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.
    Romano L; Venturi G; Giomi S; Pippi L; Valensin PE; Zazzi M
    J Med Virol; 2002 Feb; 66(2):143-50. PubMed ID: 11782921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
    Kempf DJ
    Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
    [No Abstract]   [Full Text] [Related]  

  • 30. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
    O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
    J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 32. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current knowledge and future prospects for the use of HIV protease inhibitors.
    Moyle G; Gazzard B
    Drugs; 1996 May; 51(5):701-12. PubMed ID: 8861542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
    Mitsuya H; Maeda K; Das D; Ghosh AK
    Adv Pharmacol; 2008; 56():169-97. PubMed ID: 18086412
    [No Abstract]   [Full Text] [Related]  

  • 37. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-2 Protease resistance defined in yeast cells.
    M'Barek NB; Audoly G; Raoult D; Gluschankof P
    Retrovirology; 2006 Sep; 3():58. PubMed ID: 16956392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Zachary KC; Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.